Clinical-stage biotech developing tinlarebant, an oral drug to slow vision loss in inherited and age-related retinal diseases.
Clinical-stage biotech developing tinlarebant, an oral drug to slow vision loss in inherited and age-related retinal diseases.
Has no product to sell, so its costs are paid from investor money raised in share sales. Its value hinges on late-stage trial results for tinlarebant and on regulatory approvals.
Moat: none (IP / patents). Pre-commercial; edge rests on being an oral alternative to injectable treatments for retinal disease.
Headquarters: San Diego, California, United States · Founded: 2018 · Employees: 41
Size Belite Bio, Inc. ADR (BLTE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $6.41B, the 1009th largest of 3,085 United States companies the cockpit tracks. Shares closed at $156.23 on 18 Nov 2026.
Performance Over six months the shares gained 9.0%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.
Capital Return on invested capital runs 27.5 points below its cost of capital (6.6% WACC).
Short interest Short interest is 3.4% of the free float (30 Oct 2026).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | -$464,000 | -$449,000 | -$399,000 | -$198,000 |
| EBITDA | n/a | -$83.7M | -$39.5M | -$31.3M | -$12.6M |
| Net income | -$111M | -$77.6M | -$36.1M | -$31.6M | -$12.6M |
| Free cash flow | n/a | -$37.1M | -$29.4M | -$29.9M | -$11.9M |
| Capital expenditure | n/a | $71,000 | $151,000 | $63,000 | $394,000 |
| Total debt | n/a | $429,000 | $537,000 | $886,000 | $866,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Belite Bio, Inc. ADR BLTE | $6.41B | +9% | n/a | n/a | n/a | n/a |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | 5.0× | n/a |
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 2.2× | -9.0% |
| Annexon ANNX | $671M | -30% | n/a | n/a | n/a | n/a |
| Ocugen OCGN | n/a | -46% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLTE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.1% | -2.1% | 10th highest of 21 |
| 6-month return | +9.0% | -4.6% | 6th highest of 20 |
| Distance from 52-week high | -21.9% | -20.4% | 10th lowest of 21 |
| ROIC minus cost of capital | -27.5 pp | +2.2 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 5.9× | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 4.3× | n/a | n/a |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 4.4× | 1.1% | +303.3% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 3.5× | -11.9% | +4.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 1.9× | -6.2% | +18.4% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 4.1× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 1.1× | -3.9% | +5.3% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | 9.6× | n/a | n/a |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 4.5× | 6.2% | +13.9% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 26.3× | 57.7% | +7.5% |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | 12.9× | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 8.6× | n/a | n/a |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 7.3× | 8.0% | +10.0% |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 5.8× | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | 44.3× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | 64.3× | n/a | n/a |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 7.1× | 20.2% | +13.3% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 2.1× | -6.8% | +10.8% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 7.6× | n/a | n/a |